Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)
NCT03221751 · VA Office of Research and Development · PHASE4 · terminated · last registry update 2024-02-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “staffing issues and COVID” | – | Registry record, VA Office of Research and Development |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-30Phase 3 first posted: Shaheed Mohtarma Benazir Bhutto Institue of Trauma, 0.1% xylometazoline nasal drops + Adrenaline nasal pack (NCT06801522)
- 2024-11-26Results posted on the registry: University of Maryland, Baltimore, a drug against ADRA1A (NCT03410823)
- 2024-11-26Also stopped (terminated): University of Maryland, Baltimore, a drug against ADRA1A (NCT03410823)
- 2024-09-26Phase 3 first posted: Universität Münster, Angiotensin II + Noradrenalin (NCT06615102)
- 2024-09-19Results posted on the registry: Elizabeth Berry-Kravis, 5-Hydroxytryptophan + Ergoloid Mesylates (NCT05030129)
- 2024-09-04Phase 3 first posted: Aswan University Hospital, Botulinum toxin A + Tadalafil 5mg (NCT06583590)
- 2024-08-07Phase 3 first posted: Opus Genetics, Inc, 0.75% phentolamine ophthalmic solution + Placebo (NCT06542497)
- 2024-07-12Results posted on the registry: Pfizer, Prazosin HCl 2mg + Prazosin HCl 1 mg (NCT04967443)
- 2024-07-10Results posted on the registry: Seattle Institute for Biomedical and Clinical Research, Prazosin + Placebo (NCT02965027)
- 2024-06-26Results posted on the registry: VA Office of Research and Development, prazosin hydrochloride + placebo (NCT02266329)
- 2024-06-05Phase 3 first posted: Copenhagen University Hospital, Rigshospitalet, Cociane hydrochloride 4% + Lidocaine 4% (NCT06443255)
- 2024-05-17Results posted on the registry: HALEON, Otrivine Congestion Relief (NCT05556148)
- 2024-05-01Phase 3 first posted: Universitas Indonesia, Dexmedetomidine + Fentanyl (NCT06394375)
- 2024-04-05Phase 3 first posted: Opus Genetics, Inc, phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist + Placebo (NCT06349759)
- 2024-02-29Phase 3 first posted: Helwan University, Phentolamine (NCT06286059)
- 2024-02-15Results posted on the registry: Opus Genetics, Inc, Phentolamine Mesylate Ophthalmic Solution 1% (NCT04004507)
- 2024-02-09Phase 3 first posted: Jimma University, Bromocriptine mesylate plus standard GDMT (NCT06250257)
- 2024-01-23Also stopped (terminated): Otsuka Pharmaceutical Development & Commercialization, Inc., Propranolol + Prazosin (NCT05189977)
- 2023-11-20Results posted on the registry: University of California, Los Angeles, Phenoxybenzamine + Doxazosin (NCT03176693)
- 2023-11-18Also stopped (suspended): Rennes University Hospital, Fludrocortisone + Placebo (NCT05001854)
- 2023-11-02Results posted on the registry: Indiana University, Antidepressant Medications (NCT04437485)
- 2023-10-25Phase 3 first posted: Humanitas Clinical and Research Center, Cannabidiol and β-Caryophyllene Patch (NCT06099171)
- 2023-10-16Phase 3 first posted: University of Aarhus, Noradrenalin + Phenylephrine (NCT06083948)
- 2023-08-21Results posted on the registry: Tulane University School of Medicine, amlodipine, hydralazine, terazosin or hydrochlorothiazide (NCT02046395)
- 2023-08-14Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% (NCT04620213)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision